Evidence map›Paper›PMID 41535871›Full record

ArticleBreast cancer research : BCR2026

CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer.

Yu Yan, Athira Narayan, Marzieh Mazinani, Harumi Saeki, Tao Huang, Gabi Lofland, Edward Gabrielson, Leslie Cope, Yasmine M Kanaan, Ali Afsari and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yu YanDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Athira NarayanDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marzieh MazinaniDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Harumi SaekiDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tao HuangDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Gabi LoflandDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Edward GabrielsonDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Leslie CopeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yasmine M KanaanDepartment of Microbiology, College of Medicine, Howard University, Washington, DC, USA.
Ali AfsariDepartment of Pathology, College of Medicine, Howard University, Washington, DC, USA.
Tammey NaabAthari BioSciences, Sterling, VA, USA.
Saraswati SukumarDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Martin G PomperDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. martin.pomper@utsouthwestern.edu.
Vanessa F MerinoDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vmerino1@umd.edu.

Funding

U.S. Department of Defense W81XWH-04-1-0595U.S. Department of Defense W81XWH-15-1-0017
6 · The paper itself

Abstract

Breast cancer mortality is higher in African American (AA) women than in European American women, but the molecular mechanisms remain poorly understood. Previously, we showed that β-crystallin B2 (CRYβB2) is upregulated in AA breast tumors and promotes oncogenesis via nucleolin (NCL) activation. Presently no biomarkers, other than estrogen receptor (ER)/progesterone receptor (PR) expression, are used to prescribe cyclin-dependent kinases 4/6 inhibitors (CDK4/6i) for women with hormone receptor positive (HR+) metastatic breast cancer. Here, we show that CRYβB2 overexpression drives cell cycle progression and CDK4/6 pathway activation in premalignant, ductal carcinoma in situ (DCIS), triple-negative breast cancer (TNBC), and ER⁺ breast cancer models. Targeting CRYβB2 or NCL reduced CDK4, cell division cycle 25 A (Cdc25a), and phosphorylated Rb (ppRb) levels. Tumors expressing CRYβB2 were selectively sensitive to the CDK4/6 inhibitor palbociclib, with CRYβB2 expression inversely correlating with IC₅₀ values. Knockdown of CRYβB2 conferred resistance, whereas NCL knockout or treatment with the NCL aptamer AS-1411 sensitized cells to palbociclib. In TNBC and ER+ tumors of AA patients, high CRYβB2 expression correlated with CDK4/pRb activation and decreased survival in TNBC. These results indicate that CRYβB2 drives CDK4/6 activation and may serve as a prognostic biomarker and predictor of response to palbociclib therapy.

Indexed as

Biomarkers, TumorBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceNucleolinPhosphoproteinsPiperazinesPrognosisPyridinesBiomarkers, TumorCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6NucleolinpalbociclibPhosphoproteinsPiperazinesProtein Kinase InhibitorsPyridinesRNA-Binding ProteinsAfrican AmericanCDK4CRYβB2European AmericanNucleolinPalbociclibpRb

Identifiers

PMID41535871
PMCPMC12888483

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.